Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

Rhea-AI Summary

Astria Therapeutics (Nasdaq:ATXS) has announced its upcoming presentation at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam on September 26, 2024. The company will showcase initial data from the ALPHA-STAR trial of navenibart, their treatment for hereditary angioedema.

Dr. Raffi Tachdjian from UCLA will present a poster titled 'ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes' during the e-poster showcase six at 4:20pm CEST. This presentation marks an important milestone for Astria Therapeutics in their development of therapies for allergic and immunologic diseases.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.

Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), will present a poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.” The poster will be presented in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919236987/en/

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is Astria Therapeutics presenting at the EADV Congress on September 26, 2024?

Astria Therapeutics (ATXS) will present initial navenibart ALPHA-STAR trial data for hereditary angioedema treatment at the EADV Congress in Amsterdam on September 26, 2024.

Who will present Astria Therapeutics' ALPHA-STAR trial data at the EADV Congress?

Dr. Raffi Tachdjian, Associate Clinical Professor at UCLA, will present the ALPHA-STAR trial data for Astria Therapeutics (ATXS) at the EADV Congress.

What is the focus of Astria Therapeutics' ALPHA-STAR trial?

Astria Therapeutics' (ATXS) ALPHA-STAR trial focuses on the safety and efficacy of single and multiple doses of STAR-0215 in patients with hereditary angioedema.

When and where will Astria Therapeutics' poster be presented at the EADV Congress?

Astria Therapeutics' (ATXS) poster will be presented in e-poster showcase six on Thursday, September 26, 2024, at 4:20pm CEST at the EADV Congress in Amsterdam.